How to select the most valuable anticancer drugs for reimbursement? Experience of ESMO and WHO

Poliakova D.

Summary. The constant appearance of new drugs for the treatment of oncological diseases and the need for the effective distribution of funds allocated for their purchase necessitates the search for a system of priorities and a methodology for the selection of drugs in order to maximize the positive effect.

If you notice an error, highlight the error text and press Ctrl + Enter to report it


Log in Registration Search for: Home Electronic publication Fresh number Archives Authors About Edition Subscription Requirements for authors Reviewing Editorial board
Organization of anticancer fight Tumors of the chest cavity Tumors of abdominal organs Tumors of skin, soft tissues, bones Breast tumor Oncogynecology Tumors of the head and neck Oncurology Oncohematology Radiation diagnostics, radiation therapy Experimental studies Magazine online All news	Full article in pdf format Keywords: Breakthrough Therapy, clinical benefit assessment, ESMO-MCBS, FDA, formulary, medical technology assessment, oncology treatment, protocols, TOP 10 ONKO Review: Share: All electronic publications Т. 13, № 1 (49) : Review Articles How to select the most valuable anticancer drugs for reimbursement? Experience of ESMO and WHO Poliakova D. Summary. The constant appearance of new drugs for the treatment of oncological diseases and the need for the effective distribution of funds allocated for their purchase necessitates the search for a system of priorities and a methodology for the selection of drugs in order to maximize the positive effect. If you notice an error, highlight the error text and press Ctrl + Enter to report it Follow us on social media: Related articles: Pharmacoeconomic analysis of anticancer drugs use for prostate cancer treatment Granulocyte colony stimulating factor use during anticancer therapy Treatment of patients with Hodgkin’s lymphoma after progression: chemosensitivity, transplantation and targeted drugs The activity of p53 in ovarian cancer patients, depending on the sensitivity to platinum drugs The immediate results of using preoperative chemoradiotherapy with intraarterial administration of cytostatic drugs No Comments » Add your Leave a comment Name (required) Mail (will not be published) (required) Website CAPTCHA Code
MORION Publishing House Editorial office and publisher: 02140, Kyiv, ave. Bazhana 10A Tel.: 380 (44) 585-97-10 Specialized medical online publication for doctors, pharmacists, pharmacists, medical students and pharmaceutical universities.Disclaimer morion.ua apteka.ua pharmstandart.com.ua compendium.com.ua proximaresearch.com

Magazine online

How to select the most valuable anticancer drugs for reimbursement? Experience of ESMO and WHO

No Comments » Add your

Leave a comment